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Summary Serum concentrations of the CA 19-9 antigen were determined in 91 patients with pancreatic
cancer and in 111 patients with benign pancreatic, biliary and hepatocellular diseases. The CA 19-9
concentration was above the cut-off limit (37 Uml- ') in 78% of the patients with pancreatic cancer and high
levels (>50OUml-1) were seen in 56% of these patients. Elevated levels were also seen in benign diseases
(22%), especially in patients with extrahepatic cholestasis (up to 440Uml-1). Hepatocellular jaundice and
pancreatitis were associated with normal values (84% of the patients), or with only slightly elevated CA 19-9
levels (up to 88 Uml-1). The CA 19-9 test can be useful as an additional diagnostic tool for the detection of
pancreatic cancer. Preliminary results suggest that
surgically treated patients.
The CA-19-9 radioimmunoassay is based on a
monoclonal antibody, 1116 NS 19-9, raised against
a human colorectal cell line (Koprowski et al., 1979,
1981; Del Villano et al., 1983). The antigenic
determinant is a sialylated lacto-N-fucopentaose II,
corresponding to a sialylated Lewisa blood group
substance (Magnani et al., 1981, 1982). This antigen
is present in serum in a high molecular weight
glycoprotein fraction, the mucin fraction (Magnani
et al., 1983).
Elevated serum CA 19-9 levels have previously
been found in many different malignant diseases
(Herlyn et al., 1982; Del Villano et al., 1983;
Jalanko et al., 1984; Kuusela et al., 1984; Ritts et
al., 1984). The test seems especially promising for
the detection of pancreatic cancer, 70-79% of these
patients showing increased serum CA 19-9
concentrations (Del Villano et al., 1983; Jalanko et
al., 1984; Ritts et al., 1984). Moderately elevated
values have also been found in patients with
jaundice of benign origin (Jalanko et al., 1984), but
the association of elevated CA 19-9 values and
jaundice has not been defined. Since most of the
patients with pancreatic cancer also have jaundice,
this question seems important. In this work, CA 19-
9 levels were determined in patients with pancreatic
cancer, and in patients with benign diseases
representing differential diagnostic problems in
clinical practice.
the CA 19-9 assay can be used in the monitoring of
Patients and methods
Patients
Serum samples were obtained from 91 patients with
pancreatic cancer. Eight patients had a local
resectable tumour, all other patients had either a
locally spread or a metastasized tumour. The
cancers included 2 islet cell carcinomas, 1 carcinoid
tumour of the pancreas, 3 cystadenocarcinomas, 2
anaplastic carcinomas, 13 poorly differentiated
ductal adenocarcinomas and 33 well to moderately
differentiated adenocarcinomas. In 37 patients with
an adenocarcinoma the exact degree of
differentiation could not be determined. The serum
samples were taken preoperatively. Repeated
samples were obtained from three patients, who
developed a recurrence after a radical operation,
and from nine patients with a nonresectable
tumour. Patients who had received radiotherapy to
the pancreatic region were excluded from the
present study.
A total of 56 patients had a benign pancreatic
disease, including severe haemorrhagic pancreatitis
(25 patients), non-haemorrhagic acute pancreatitis
(19 patients), acute pancreatitis associated with
pseudocyst formation (4 patients) and chronic
pancreatitis (8 patients). Benign biliary tract
diseases were found in 31 patients. These included
13 patients with common bile duct stones and
cholestasis. One patient had cholestasis due to
benign postoperative stenosis. Four patients had
bile duct stones without jaundice, and 13 patients
had gallbladder stones with an acute or chronic
inflammation of the gallbladder. Control samples
were obtained postoperatively from 3 of the
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patients with benign obstructive jaundice after
recovery, when their bilirubin values were normal.
Hepatocellular jaundice was due to hepatic cirrhosis
in 11 patients, and due to acute alcoholic hepatitis
in 3 patients. Ten patients had viral hepatitis.
Assays
CA 19-9 antigen concentration was determined by a
solid phase radioimmunoassay (Centocor, Malvern,
PA, USA), using the recommended cut-off value of
37 Uml-' (Del Villano et al., 1983). The serum
samples were stored at -20°C or -70°C from 1
to 24 months before the CA 19-9 measurements.
Carcinoembryonic antigen (CEA) was quantitated
either by the double antibody radioimmunoassay,
in which commercial anti-CEA antiserum
(Dakopatts a/s, Copenhagen, Denmark) was used
as the first antibody (Rutanen et al., 1978), or by
the Abbott-CEA-RIA Diagnostic Kit (Abbott,
Weisbahn, FRG). These two tests have shown a
good correlation (Jalanko et al., 1984). A cut-off
value of 2.5 ngml-1 was used.
Routine laboratory data
Serum bilirubin and serum alkaline phosphatase
values were obtained from clinical records, when
available. Cut-off values of 20jmolI' and
280 Uml-', respectively, were used.
Results
CA 19-9 in pancreatic cancer
The range of serum CA 19-9 concentration in the 91
patients was <6.2-300000Um-m and the median
value was 705Uml-'. Seventy-one of the patients
with pancreatic cancer (78%) had a serum CA 19-9
concentration >37 Uml-' (Figure 1, Table I), and
more than half (56%) of these patients had a
concentration >500 Uml-1 (Table II). High levels
were found especially in patients with widely
disseminated disease, but also 5 out of 8 patients
with a resectable pancreatic tumour had elevated
values (range: 34-12500 Uml-1). The concen-
tration was increased in 25 out of 33 patients (76%)
with a well to moderately differentiated adeno-
caricinoma and in 11 out of 15 patients (73%) with a
poorly differentiated or an anaplastic carcinoma. All
three patients with a cystadenocarcinoma had a
clearly increased serum CA 19-9 concentration. Two
patients with an islet cell carcinoma had a normal
CA 19-9 level, while in one patient with a carcinoid
tumour, the level was slightly elevated, 48 Uml-1.
Changes in the serum CA 19-9 values were
followed in 11 patients. In 2 surgically treated
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Figure 1 Serum CA 19-9 concentrations in patients
with localized (a) and advanced (a) pancreatic
cancer; and with acute (0) and chronic (A)
pancreatitis; benign biliary tract diseases with (0) and
without ([1) jaundice and hepatocellular diseases. The
cut-off value for the CA 19-9 test is marked as a
dashed line.
patients the CA 19-9 level was elevated pre-
operatively, decreased after surgery and began to
increase 4 and 8 months before appearance of
symptoms or signs of recurrence. In the third
patient, the preoperative value was 36 Uml-1, it
decreased after the operation, and increased above
the cut-off level after the clinical detection of
recurrence (Figure 2). The CA 19-9 concentration
increased with tumour progression in 5 patients,
who underwent by-pass surgery, and in 3
conservatively treated patients. The level decreased
after by-pass surgery (from 2850 to 845Uml-P) in
one patient with preoperative jaundice and a
normal serum bilirubin by the time of control (6
weeks postoperatively).
CA 19-9 in benign diseases
Nine of 56 of the patients (16%) with pancreatitis
had a slightly increased CA 19-9 concentration _a111n
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Table I Serum CA 19-9 concentrations in patients with pancreatic cancer and with benign pancreatic,
biliary tract and hepatocellular diseases, using various cut-off levels
CA 19-9
Diagnosis No. tested >37Uml-1 >10OUml- >300Uml- >500UmlW-
Pancreatic cancer 91 78% 73% 63% 56%
Pancreatitis 56 16% 0% 0% 0%
Benign biliary disease 31 35% 23% 6% 0%
Hepatocellular jaundice 24 17% 0% 0% 0%
Table II Assay parameters for the CA 19-9 and the CEA assays, and for the
combination of the tests
CA 19-9+ CA 19-9+
Assay parameter CA 19-9+a CEA +b or CEA+ and CEA+
Sensitivity' 78% 54% 85% 47%
Specificityd 78% 76% 62% 92%
Predictive value' 75% 68% 68% 85%
aCA 19-9+: >37 UmI -1. bCEA+: >2.5 ngml - . 'Sensitivity =TP/(TP+FN).
dSpecificity =TN/(TN+FP). ePredictive value=TP/(TP+FP). TP =true positive;
FN=false negative; TN =true negative; FP=false positive.
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Figure 2 CA 19-9 (a) and CEA (b) levels in three patients, who underwent pancreaticoduodenectomy for
pancreatic cancer, and developed a recurrence. The arrows indicate the time of clinical verification of the
recurrence.
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(range: <6.2-88 Uml- 1). No clear difference
between acute and chronic pancreatitis was
observed (Figure 1, Table I).
Elevated CA 19-9 levels were found in 11 of 31
patients (35%) with a benign biliary disease (range:
<6.2-440 Uml-1) (Figure 1, Table I). Nine patients
with an elevated CA 19-9 value had a common bile
duct stone with jaundice, and 2 had acute cholecys-
titis without jaundice. In 3 of the patients with
common bile duct stones and obstructive jaundice
the values had decreased to normal 6 to 14 months
after removal of the stones.
Four of the 24 patients (17%) with hepatocellular
jaundice had a slightly increased CA 19-9
concentration (range: <6.2-65 Uml-') (Figure 1,
Table I).
Comparison ofCA 19-9 and CEA
The CA 19-9 assay had a higher sensitivity (78%)
for pancreatic cancer than the CEA test (54%).
Using a cut-off level of 5ngml-', as commonly
used today, the sensitivity was 44% for CEA. There
was no correlation (r=0.08) between the con-
centrations of these two markers (Figure 3). The
assay parameters for the CA 19-9 and the CEA
assays, and for the combination of the tests are
summarized in Table II. Interestingly, sera from 27
patients with pancreatic cancer displayed a
pathological CA 19-9 level, while the CEA
concentration was normal. The opposite was true in
6 patients (Figure 3). Either of the markers was
elevated in 85% of the cancer patients (Table II).
Correlation ofCA 19-9, bilirubin and alkaline
phosphatase
No correlation between the CA 19-9 concentration
and bilirubin (r=0.36) or alkaline phosphatase
(r=0.10) levels was seen (Figures 4 and 5). The
highest false-positive values were, however, found in
patients with benign obstructive jaundice and with
high bilirubin and alkaline phosphatase levels.
Discussion
Elevated CA 19-9 levels have been found in many
gastrointestinal adenocarcinomas, such as pan-
creatic cancer (70-79%), biliary tract cancer (73%),
gastric cancer (42-62%), colorectal cancer (18-37%),
and hepatocellular carcinoma (22%). On the basis
of earlier reports the CA 19-9 assay seems to be a
promising tumour marker for the detection of
pancreatic cancer (Herlyn et al., 1982; Del Villano
et al., 1983; Jalanko et al., 1984; Kuusela et al.,
1984; Ritts et al., 1984).
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Figure 3 Comparison of the CA 19-9 and CEA
concentrations in patients with pancreatic cancer (0)
and with benign pancreatic, biliary tract and
hepatocellular diseases (0). The cut-off values for the
assays are marked as dashed lines. Both markers were
measured in 87 patients with pancreatic cancer and in
91 patients with benign disease.
In our material the CA 19-9 level was elevated in
78% of patients with pancreatic cancer. Sixty
percent of all cancer patients, but only 3 of 8 of the
patients with a resectable tumour, had a higher
serum CA 19-9 level than any of those with a
benign disease. A differential diagnostic problem
was found in patients with a moderately elevated
CA 19-9 level (37-500Uml-') and jaundice. In this
group we could not differentiate between benign
and malignant diseases using CA 19-9 alone, or in
combination with CEA, bilirubin or alkaline
phosphatase. In patients without jaundice a serum
CA 19-9 level above 100 Uml-1 was highly
suggestive of cancer, whereas in patients with
clearly elevated levels of bilirubin (>100 imoll-')
or alkaline phosphatase (>700 UI 1), a higher cut-
off level, 50OUml-1, was required. In our material
elevated CA 19-9 values were more often found in
benign pancreatic and biliary diseases than has been
reported by other groups (Herlyn et al., 1982; Del
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Figure 4 Comparison of the CA 19-9 and bilirubin
concentrations in patients with pancreatic cancer (0),
and with benign pancreatic, biliary tract and
hepatocellular diseases (0).
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Figure 5 Comparison of the CA 19-9 and alkaline
phosphatase concentrations in patients with pancreatic
cancer (0), and with benign pancreatic, biliary tract
and hepatocellular diseases (0).
Villano et al., 1983; Ritts et al., 1984). The
explanation for this discrepancy is probably due to
differences in the control groups.
To exclude the possibility that jaundice itself
might be the reason for a false-positive CA 19-9
level, a patient group with hepatocellular jaundice
was studied. Only 17% of these patients showed a
slightly elevated level. This, and the fact that no
correlation was found between the levels of CA 19-
9, bilirubin and alkaline phosphatase, suggest that
the elevation of the CA 19-9 levels in extrahepatic
cholestasis might be due to increased pressure in
the common bile duct, usually combined with an
increased pressure in the pancreatic duct. The
obstruction of the common bile duct and the
pancreatic duct caused by cancers in the head of the
pancreas may contribute to the elevated CA 19-9
concentrations seen in these patients. The effect of
increased pressure in the pancreatic duct upon the
serum CA 19-9 level and on the concentration of
CA 19-9 in the pancreatic juice should further be
studied. It would also be important to know the
function of the liver in metabolizing and excreting
CA 19-9.
Eighteen patients with pancreatic cancer had a
normal serum bilirubin and still a clearly elevated
CA 19-9. This may be caused either by obstruction
of pancreatic ducts or is due to an increased
secretion of the CA 19-9 antigen by the tumour
itself. The results of an immunohistochemical study
of the tissue expression of CA 19-9 in pancreatic
cancer and in pancreatitis support both these
mechanisms (Haglund et al., 1986).
The serum CA 19-9 concentrations in cancer
patients tended to increase during progression of
the disease, suggesting that the marker levels are
related to tumour burden. The histological type of
the tumour, however, have some effect on the serum
concentration, since a very high serum value
(3100Uml-1) was found in a patient with a
. f
104
O 0
103202 C. HAGLUND et al.
cystadenocarcinoma of only 2 cm diameter. This
finding also speaks for an increased production of
CA 19-9 by the tumour itself.
Normal CA 19-9 values were found in 22% of the
patients with pancreatic cancer. Some of these
patients had a small tumour burden, but even large
tumours were occasionally associated with a normal
serum level. The reason for this is unknown.
Negative values (<6.2 Uml-') were seen in 5% of
the cancer patients. Since the CA 19-9 antigen is
related to the Lewis blood group substance,
individuals who are Lewisa-b- (5% of the
population) cannot produce the CA 19-9 antigen.
Whether this fact explains the negative CA 19-9
values in this study is still unclear.
With current diagnostic methods pancreatic
cancer can be difficult to distinguish from benign
conditions, which in many respects resemble cancer
of the pancreas. The CA 19-9 test seems to be a
useful additional tool in the diagnosis of pancreatic
cancer, although the clinician should be aware of
the possibilities of false-positive and negative
values. The CA 19-9 assay also seems promising in
the postoperative monitoring of surgically treated
patients.
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